Latest danazol Stories

GREENWOOD VILLAGE, Colo., Feb. 27, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema. The trial will evaluate Optina(TM) in adults with recent onset diabetic macular edema. Last year, the FDA granted Optina(TM) 505(b)(2) status and drugs designated under this pathway can be approved on a single trial. (Logo:...

GREENWOOD VILLAGE, Colo., Jan. 22, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) announced today that the FDA has accepted the Company's IND for Optina(TM) for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina(TM) 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial. (Logo:...

GREENWOOD VILLAGE, Colo., May 31, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that The European Patent Office (EPO) has notified the company that it will grant a patent covering Ampio's Optina(TM)( )product. The patent will protect...

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina(TM). Ampio also received a notice of allowance of a...

GREENWOOD VILLAGE, Colo., Oct. 18, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has demonstrated in an IRB approved, randomized, placebo controlled, double-blinded proof of concept study, that low dose intranasal danazol has an impact on allergic rhinitis, a clinical condition in which increases in vascular...

May have comparable benefits with fewer side effects than conventional drug treatmentChinese herbal medicine (CHM) may relieve symptoms in the treatment of endometriosis. A systematic review by Cochrane Researchers found some evidence that women had comparable benefits following laparoscopic surgery and suffered fewer adverse effects if they were given Chinese herbs compared with conventional drug treatments.Endometriosis is a gynecological disorder affecting as many as one in six women of...

Research and Markets (http://www.researchandmarkets.com/research/5d1b74/womens_health_ser) has announced the addition of Decision Resources, Inc.'s new report "Women's Health Series: Endometriosis -- How Will New Therapies Compare with Current Market Leaders?" to their offering. This report, along with the other reports in the Women's Health Series, includes primary research with thought-leading clinicians. We conducted an in-depth survey with obstetricians/gynecologists who have...

By Trivedi, Prakash Selvaraj, Kamala; Mahapatra, P Das; Srivastava, Saroj; Malik, Sonia Abstract An open, prospective, multicenter study was designed to assess the efficacy and safety of dydrogesterone in the post- laparoscopic treatment of endometriosis in Indian patients. Ninety- eight patients suffering from minimal, mild, moderate or severe endometriosis, with or without infertility, who had undergone laparoscopy, were treated with dydrogesterone 10 mg/day (or 20 mg/ day in severe cases)...

By Duvvur, S Khan, F; Powell, K Abstract Hereditary Angioedema is a rare but potentially life threatening condition. It is important that Obstetricians are aware of this condition as it affects women in the reproductive years and thus its recognition and proper management in pregnancy is crucial. Keywords: Pregnancy, Hereditary Angioedema, C-1 esterase inhibitor The case NB, a 34-year-old woman was diagnosed with hereditary angioedema (HAE) at the age of 10 years because of recurrent...